Neurocrine Biosciences, Inc. (NBIX) Soleno Therapeutics, Inc. - M&A Call - Slideshow

Neurocrine Biosciences announced its acquisition of Soleno Therapeutics in April 2026, detailing the deal’s strategic rationale in a corporate slideshow during an M&A call. The transaction expands Neurocrine’s rare disease portfolio, specifically targeting Soleno’s late-stage candidate for Prader-Willi syndrome, a genetic obesity disorder with no approved therapies. Financial terms were not disclosed in the slideshow, but the presentation emphasized Soleno’s lead asset as a near-term revenue driver with potential blockbuster status in underserved metabolic markets. Neurocrine highlighted synergies in commercialization and R&D, leveraging its existing infrastructure to accelerate Soleno’s pipeline while reducing operational redundancies post-acquisition. Investor materials underscored the deal’s alignment with Neurocrine’s long-term growth strategy, focusing on high-unmet-need indications and diversifying beyond its core neurology and endocrinology franchises.